SELLAS Life Sciences Group, Inc. — Director's Dealing 2011

Apr 20, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-04-20

Reporting Person: Ahn Mark J (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-04-20	Common Stock, par value $.0001	P	10000	$0.95	Acquired	10000	Direct